Pediatr. praxi. 2026;27(4):227-234 | DOI: 10.36290/ped.2026.038

Comprehensive management of the pediatric neuro-oncology patient

MUDr. Jana Táborská, Ph.D.1, 2, doc. MUDr. Michal Zápotocký, Ph.D.2, 3, doc. MUDr. Vladimír Beneš III., Ph.D.1, 2
1 Neurochirurgická klinika dětí a dospělých 2. lékařské fakulty a Fakultní nemocnice Motol a Homolka, Praha
2 Centrum dětské neuroonkologie 2. lékařské fakulty a Fakultní nemocnice Motol a Homolka, Praha
3 Klinika dětské hematologie a onkologie 2. lékařské fakulty a Fakultní nemocnice Motol a Homolka, Praha

Among pediatric malignancies, central nervous system (CNS) tumors represent the leading cause of cancer-related mortality. The overall five-year survival rate for pediatric patients with brain tumors is around 80 %. However, survival outcomes vary significantly across specific diagnoses. The heterogeneity of these diagnoses, along with anatomical locations and other clinical variables, results in substantial variability in the available therapeutic modalities for each individual patient. The cornerstone of pediatric brain tumor management is a comprehensive, multidisciplinary asses­sment of the patient, carefully weighing the treatment options and their associated risks. Centralizing patients into specialized treatment centers allows for the optimal prevention of complications, facilitates interdisciplinary coordination, and ensures a systematic approach to both postoperative and long-term follow-up care.

Keywords: comprehensive management, neurooncology, brain tumors, pediatric neurosurgery.

Accepted: September 3, 2026; Published: September 17, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Táborská J, Zápotocký M, III VB. Comprehensive management of the pediatric neuro-oncology patient. Pediatr. praxi. 2026;27(4):227-234. doi: 10.36290/ped.2026.038.
Download citation

References

  1. Krejci D, Karolyi M, Pehalova L, et al. Development of the Czech Childhood Cancer Information System: Data Analysis and Interactive Visualization. JMIR Public Health Surveill. 2021; 6:e23990. doi: 10.2196/23990. Go to original source...
  2. Ostrom QT, Price M, Ryan K, et al. CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2022; Suppl 3: iii1-iii38. doi: 10.1093/neuonc/noac161. Go to original source... Go to PubMed...
  3. Bandopadhayay P, Bergthold G, London WB, et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014;7:1173-1179. doi: 10.1002/pbc.24958. Go to original source... Go to PubMed...
  4. Kozyrev DA, Soleman J, Tsering D, et al. Pediatric thalamic incidentalomas: an international retrospective multicenter study. J Neurosurg Pediatr. 2022;2:141-149. doi: 10.3171/2021.6.PEDS20976. Go to original source...
  5. Taborska J, Horcicakova K, Bubenikova A, et al. Pediatric thalamic incidentalomas: a retrospective analysis of their characteristics, evolution, management, and prognostic factors for progression. Acta Neurochir (Wien). 2025;1:218. doi: 10.1007/s00701-025-06632-2. Go to original source...
  6. Zhang H, Liu K, Ba R, et al. Histological and molecular classifications of pediatric glioma with time- dependent diffusion MRI-based microstructural mapping. Neuro Oncol. 2023;6: 1146-1156. doi: 10.1093/neuonc/noad003. Go to original source...
  7. Plasse A, Levy R, Tauziede-Espariat A, et al. MRI-Based Score to Recognize Thalamic Glioma Grade in Children: Morphology, Diffusion, and Arterial-Spin-Labeling Perfusion. Pediatr Blood Cancer. 2025;7:e31704. doi: 10.1002/pbc.31704. Go to original source...
  8. Gnekow AK, Kandels D, Tilburg CV, et al. SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma. Klin Padiatr. 2019; 3:107-135. doi: 10.1055/a-0889-8256. Go to original source... Go to PubMed...
  9. Smith ER, Butler WE, Barker FG. Craniotomy for resection of pediatric brain tumors in the United States, 1988 to 2000: effects of provider caseloads and progressive centralization and specialization of care. Neurosurgery. 2004;3:553-563; discussion 563-555. doi: 10.1227/01.neu.0000108421.69822.67. Go to original source... Go to PubMed...
  10. Drapeau AI, Onwuka A, Koppera S, et al. Hospital Case-Volume and Patient Outcomes Following Pediatric Brain Tumor Surgery in the Pediatric Health Information System. Pediatr Neurol. 2022;48-54. doi: 10.1016/j.pediatrneurol.2022.06.002. Go to original source... Go to PubMed...
  11. Laustsen AF, Avula S, Gronbaek J, et al. Tumour volume as a predictor of postoperative speech impairment in children undergoing resection of posterior fossa tumours: a prospective, multicentre study. Acta Neurochir (Wien). 2025;1:97. doi: 10.1007/s00701-025-06459-x. Go to original source...
  12. Sarup R, Laustsen AF, Sorensen MK, et al. Glucocorticoid use in paediatric posterior fossa tumour surgery and the occurrence of postoperative speech impairment. Childs Nerv Syst. 2025;1:231. doi: 10.1007/s00381-025-06850-0. Go to original source... Go to PubMed...
  13. Benes V, 3rd, Zapotocky M, Liby P, et al. Survival and functional outcomes in paediatric thalamic and thalamopeduncular low grade gliomas. Acta Neurochir (Wien). 2022;6:1459-1472. doi: 10.1007/s00701-021-05106-5. Go to original source... Go to PubMed...
  14. Bubenikova A, Haratek K, Taborska J, et al. Long-term prognosis and treatment outcomes in infantile and neonatal brain tumors. Childs Nerv Syst. 2025;1:251. doi: 10.1007/s00381-025-06881-7. Go to original source... Go to PubMed...
  15. Entenmann CJ, Bubenikova A, Blazkova J, Jr., et al. Evaluation of the growth rates and related prognostic factors in radiation-induced meningiomas. J Neurooncol. 2023;1:155-163. doi: 10.1007/s11060-022-04209-y. Go to original source... Go to PubMed...
  16. Taborska J, Bubenikova A, Skalicky P, et al. Prognostic factors of thalamic and thalamopeduncular low-grade gliomas in children: A systematic review and recommendations for surgical management. Brain Spine. 2025;104183. doi: 10.1016/j.bas.2025.104183. Go to original source...
  17. Krishnatry R, Zhukova N, Guerreiro Stucklin AS, et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. Cancer. 2016;8:1261-1269. doi: 10.1002/cncr.29907. Go to original source...
  18. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;16:2570-2575. doi: 10.1200/jco.2005.03.8349. Go to original source... Go to PubMed...
  19. Neervoort FW, Van Ouwerkerk WJ, Folkersma H, et al. Surgical morbidity and mortality of pediatric brain tumors: a single center audit. Childs Nerv Syst. 2010;11:1583-1592. doi: 10.1007/s00381-010-1086-1. Go to original source... Go to PubMed...
  20. Thomale UW, Gnekow AK, Kandels D, et al. Long-term follow-up of surgical intervention pattern in pediatric low-grade gliomas: report from the German SIOP-LGG 2004 cohort. J Neurosurg Pediatr. 2022;3:316-329. doi: 10.3171/2022.6.PEDS22108. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.